Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.
Choudhury AD, Kwak L, Cheung A, Allaire KM, Marquez J, Yang DD, Tripathi A, Kilar JM, Flynn M, Maynard B, Reichel R, Pace AF, Chen BK, Van Allen EM, Kilbridge K, Wei XX, McGregor BA, Pomerantz MM, Bhatt RS, Sweeney CJ, Bubley GJ, Jacene HA, Taplin ME, Huang FW, Harshman LC, Fong L. Choudhury AD, et al. Among authors: bhatt rs. Cancer Immunol Res. 2024 Mar 29:OF1-OF15. doi: 10.1158/2326-6066.CIR-22-0306. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38552171
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. Ross RW, et al. Among authors: bhatt rs. Cancer. 2012 Oct 1;118(19):4777-84. doi: 10.1002/cncr.27416. Epub 2012 Jan 26. Cancer. 2012. PMID: 22282219 Free PMC article. Clinical Trial.
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.
Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, Choueiri TK, Signoretti S. Lalani AA, et al. Among authors: bhatt rs. Oncotarget. 2017 Oct 23;8(61):103428-103436. doi: 10.18632/oncotarget.21952. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262573 Free PMC article.
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward.
Harshman LC, Drake CG, Haas NB, Manola J, Puligandla M, Signoretti S, Cella D, Gupta RT, Bhatt R, Van Allen E, Lara P, Choueiri TK, Kapoor A, Heng DYC, Shuch B, Jewett M, George D, Michaelson D, Carducci MA, McDermott D, Allaf M. Harshman LC, et al. Kidney Cancer. 2017 Jul 26;1(1):31-40. doi: 10.3233/KCA-170010. Kidney Cancer. 2017. PMID: 30334002 Free PMC article. Review.
Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.
Gjyrezi A, Xie F, Voznesensky O, Khanna P, Calagua C, Bai Y, Kung J, Wu J, Corey E, Montgomery B, Mace S, Gianolio DA, Bubley GJ, Balk SP, Giannakakou P, Bhatt RS. Gjyrezi A, et al. Among authors: bhatt rs. J Clin Invest. 2020 Jun 1;130(6):3287-3298. doi: 10.1172/JCI132184. J Clin Invest. 2020. PMID: 32478682 Free PMC article.
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.
McKay RR, Kwak L, Crowdis JP, Sperger JM, Zhao SG, Xie W, Werner L, Lis RT, Zhang Z, Wei XX, Lang JM, Van Allen EM, Bhatt RS, Yu EY, Nelson PS, Bubley GJ, Montgomery RB, Taplin ME. McKay RR, et al. Among authors: bhatt rs. Clin Cancer Res. 2021 Jul 1;27(13):3610-3619. doi: 10.1158/1078-0432.CCR-20-4616. Epub 2021 Apr 13. Clin Cancer Res. 2021. PMID: 33849963 Free PMC article. Clinical Trial.
153 results